VALIC Company I Health Sciences
Name
As of 04/16/2021Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-46.5%
1 yr return
48.9%
3 Yr Avg Return
18.3%
5 Yr Avg Return
16.9%
Net Assets
$966 M
Holdings in Top 10
28.0%
52 WEEK LOW AND HIGH
$14.8
$14.81
$29.83
Expenses
OPERATING FEES
Expense Ratio 1.09%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 37.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$0
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 04/16/2021Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
VCHSX - Profile
Distributions
- YTD Total Return -46.5%
- 3 Yr Annualized Total Return 18.3%
- 5 Yr Annualized Total Return 16.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.18%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameVALIC Company I Health Sciences Fund
-
Fund Family NameVALIC
-
Inception DateNov 01, 2000
-
Shares OutstandingN/A
-
Share ClassNo Load
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerZiad Bakri
Fund Description
VCHSX - Performance
Return Ranking - Trailing
| Period | VCHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -46.5% | -46.5% | 19.7% | 100.00% |
| 1 Yr | 48.9% | 21.1% | 184.4% | 27.88% |
| 3 Yr | 18.3%* | 1.3% | 54.0% | 12.33% |
| 5 Yr | 16.9%* | 5.2% | 40.3% | 16.43% |
| 10 Yr | 18.7%* | 9.4% | 20.2% | 6.45% |
* Annualized
Return Ranking - Calendar
| Period | VCHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 20.0% | -13.6% | 178.2% | 29.01% |
| 2022 | 18.1% | 3.8% | 63.8% | 71.23% |
| 2021 | -10.4% | -49.7% | 21.5% | 74.64% |
| 2020 | 13.1% | -59.8% | 54.4% | 66.91% |
| 2019 | -24.2% | -36.6% | 11.6% | 89.92% |
Total Return Ranking - Trailing
| Period | VCHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -46.5% | -46.5% | 19.7% | 100.00% |
| 1 Yr | 48.9% | 14.7% | 184.4% | 26.67% |
| 3 Yr | 18.3%* | 1.3% | 54.0% | 12.33% |
| 5 Yr | 16.9%* | 5.0% | 40.3% | 16.43% |
| 10 Yr | 18.7%* | 9.3% | 20.2% | 6.45% |
* Annualized
Total Return Ranking - Calendar
| Period | VCHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 20.0% | -13.6% | 178.2% | 29.01% |
| 2022 | 18.1% | 3.8% | 63.8% | 71.23% |
| 2021 | -10.4% | -25.3% | 22.2% | 76.09% |
| 2020 | 13.1% | -10.8% | 54.4% | 76.47% |
| 2019 | -24.2% | -36.6% | 11.6% | 96.12% |
NAV & Total Return History
VCHSX - Holdings
Concentration Analysis
| VCHSX | Category Low | Category High | VCHSX % Rank | |
|---|---|---|---|---|
| Net Assets | 966 M | 2.48 M | 47.6 B | 49.71% |
| Number of Holdings | 267 | 26 | 450 | 4.57% |
| Net Assets in Top 10 | 276 M | 239 K | 19.6 B | 52.57% |
| Weighting of Top 10 | 27.97% | 7.6% | 77.3% | 85.71% |
Top 10 Holdings
- UnitedHealth Group Inc 5.48%
- Thermo Fisher Scientific Inc 3.55%
- Eli Lilly and Co 3.32%
- Intuitive Surgical Inc 3.16%
- Danaher Corp 2.84%
- Stryker Corp 2.35%
- Regeneron Pharmaceuticals Inc 2.12%
- Amgen Inc 2.02%
- Merck & Co Inc 1.92%
- Vertex Pharmaceuticals Inc 1.88%
Asset Allocation
| Weighting | Return Low | Return High | VCHSX % Rank | |
|---|---|---|---|---|
| Stocks | 97.19% | 82.66% | 105.23% | 73.71% |
| Preferred Stocks | 1.66% | 0.00% | 5.58% | 5.14% |
| Other | 0.79% | -26.63% | 10.48% | 17.71% |
| Cash | 0.36% | -0.23% | 17.34% | 65.14% |
| Convertible Bonds | 0.00% | 0.00% | 0.02% | 59.43% |
| Bonds | 0.00% | 0.00% | 18.37% | 61.71% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | VCHSX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.85% | 22.48% | 100.00% | 60.00% |
| Basic Materials | 0.65% | 0.00% | 3.70% | 20.57% |
| Financial Services | 0.43% | 0.00% | 10.87% | 17.71% |
| Technology | 0.05% | 0.00% | 27.24% | 17.14% |
| Energy | 0.03% | 0.00% | 0.03% | 0.57% |
| Utilities | 0.00% | 0.00% | 1.24% | 58.86% |
| Real Estate | 0.00% | 0.00% | 6.18% | 62.29% |
| Industrials | 0.00% | 0.00% | 6.41% | 62.86% |
| Communication Services | 0.00% | 0.00% | 13.17% | 61.14% |
| Consumer Defense | 0.00% | 0.00% | 30.57% | 59.43% |
| Consumer Cyclical | 0.00% | 0.00% | 14.05% | 61.71% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | VCHSX % Rank | |
|---|---|---|---|---|
| US | 87.39% | 58.67% | 101.51% | 33.71% |
| Non US | 9.80% | 0.00% | 40.32% | 65.14% |
VCHSX - Expenses
Operational Fees
| VCHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.09% | 0.08% | 25.14% | 45.88% |
| Management Fee | 0.98% | 0.00% | 1.25% | 88.00% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | 0.06% | 0.03% | 0.25% | 14.29% |
Sales Fees
| VCHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| VCHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| VCHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 37.00% | 0.70% | 252.00% | 40.00% |
VCHSX - Distributions
Dividend Yield Analysis
| VCHSX | Category Low | Category High | VCHSX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 0.96% | 66.29% |
Dividend Distribution Analysis
| VCHSX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Annually | Annually |
Net Income Ratio Analysis
| VCHSX | Category Low | Category High | VCHSX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.18% | -2.53% | 1.74% | 60.23% |
Capital Gain Distribution Analysis
| VCHSX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
VCHSX - Fund Manager Analysis
Managers
Ziad Bakri
Start Date
Tenure
Tenure Rank
Apr 01, 2016
5.0
5.0%
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.04 | 23.56 | 7.25 | 20.93 |